Corvus Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
7analysts covering
FY EPS (est.)
-$0.78next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly236.7MTarget: Sufficient to fund operations into the second quarter of 2028
Soquelitinib Phase 3 PTCL Trial Enrollment QuarterlyTarget: 150 patients
Soquelitinib Phase 2 Atopic Dermatitis Trial Enrollment QuarterlyTarget: Approximately 200 patients
Watch Items
- Soquelitinib Phase 3 Peripheral T-Cell Lymphoma (PTCL) Clinical Trial Data ReadoutTrigger: Pivotal progression-free survival (PFS) data releaseAction: Evaluate clinical efficacy and safety profile to prepare for potential NDA submission
- Soquelitinib Phase 2 Atopic Dermatitis (AD) Clinical Trial ProgressTrigger: Completion of 12-week treatment course and 90-day follow-up across 4 cohortsAction: Analyze dose-dependent EASI and IGA responses to determine optimal Phase 3 dosing
- Angel Pharmaceuticals Collaboration and Clinical Progress in ChinaTrigger: Initial Phase 1b atopic dermatitis data release in ChinaAction: Assess geographic expansion progress and clinical validation of ITK inhibition in Asian populations
Research as of 19 Jun 2026